# Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.

> **NCT01838694** · PHASE1,PHASE2 · COMPLETED · sponsor: **Invion, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **BIOLOGICAL:** Ala-Cpn10
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01838694
- **Lead sponsor:** Invion, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01838694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01838694, "Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01838694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*